Table II.
T-LGLL treatment.
| Treatment | N (%) |
|---|---|
| First-line treatment | N = 47 |
| Methotrexate | 29 (62) |
| Cyclosporine | 9 (19) |
| BNZ-1 | 4 (9) |
| Chemotherapy | 3 (6) |
| Alemtuzumab | 1 (2) |
| Chlorambucil | 1 (2) |
| Prednisone with first-line treatment | |
| Yes | 12 (26) |
| No | 35 (74) |
| First-line treatment response | |
| Methotrexate | 3 (10) CR, 9 (31) PR |
| Cyclosporine | 0 (0) CR, 2 (22) PR |
| Others | 0 (0) CR, 0 (0) PR |
| Second-line treatment | N = 24 |
| Cyclophosphamide | 10 (42) |
| Methotrexate | 8 (33) |
| Cyclosporine | 2 (8) |
| Pentostatin | 1 (4) |
| BNZ-1 | 1 (4) |
| Splenectomy | 2 (8) |
| Second-line treatment response | |
| Cyclophosphamide* | 3 (30) CR, 4 (40) PR |
| Methotrexate | 0 (0) CR, 4 (57) PR |
| Cyclosporine | 0 (0) CR, 0 (0) PR |
| Splenectomy | 0 (0) CR, 1 (50) PR |
| Others | 0 (0) CR, 1 (50) PR |
| Third-line treatment | N = 13 |
| Alemtuzumab | 3 (23) |
| Cyclosporine | 4 (31) |
| Methotrexate | 3 (23) |
| Cyclophosphamide | 1 (8) |
| Romidepsin | 1 (8) |
| Duvelisib | 1 (8) |
| Fourth-line or greater treatment | |
| Pentostatin | 2 |
| Cyclophosphamide | 2 |
| Tacrolimus | 1 |
| Methotrexate | 1 |
| Alemtuzumab | 1 |
| Romidepsin | 1 |
| Siltuximab | 1 |
| Duvelisib | 1 |
| Selinexor | 1 |
*
Seven of seven patients treated with Cy after methotrexate attained a response (three CR, four PR).